INCY

A comparison of two medical-biomedical and genetics stocks reveals that Incyte (INCY) is the more attractive value investment option. INCY holds a Zacks Rank #2 (Buy) with improving earnings outlook and a Value grade of B, while Techne (TECH) has a Zacks Rank #3 (Hold) and Value grade of D. INCY's lower PEG ratio (2.67 vs 7.53) and P/B ratio (3.94 vs 5.38) suggest better valuation metrics.

Incyte Corporation and Genmab A/S have entered into a clinical trial collaboration to evaluate a combination therapy for first-line treatment of metastatic colorectal cancer (mCRC) with KRAS G12D mutations. The combination includes Incyte's INCB161734 (KRAS G12D inhibitor), Genmab's petosemtamab (bispecific antibody), and standard chemotherapy. Genmab will lead the phase I/II study while Incyte provides the drug and shares development costs.